Why AstraZeneca May Dominate the Coronavirus Vaccine Market
All eyes have been on the leaders in the coronavirus vaccine race these past few weeks. Pfizer and Moderna reported 95% efficacy and 94.5% efficacy, respectively. One dosing regimen in AstraZeneca's trial produced 90% efficacy -- but the average of its two tested dosing regimens only showed 70% efficacy.